EU Approves Trastuzumab Emtansine for HER2 Breast Cancer EU Approves Trastuzumab Emtansine for HER2 Breast Cancer

Kadcyla, the novel product that links trastuzumab with a cytotoxic, has been approved in the European Union (EU) for HER2 metastatic breast cancer. International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news